Clinical management and associated costs for moderate and severe Alzheimer's disease in urban China: a Delphi panel

Xin Yu1, Shengdi Chen2, Xiaochun Chen3

  • 1Institute of Mental Health, Peking University Sixth Hospital, Huayuanbeilu 51, Haidian District, Beijing, 100191 China.

Insights

This study clarifies healthcare resource use and costs for moderate to severe Alzheimer's disease (AD) in China. Findings aid policymakers in planning and economic evaluations for AD patient care.

Area of Science:

  • Gerontology
  • Public Health
  • Health Economics

Background:

  • Healthcare resource utilization for Alzheimer's disease (AD) in China remains poorly understood.
  • This study addresses the need for data on clinical management and associated costs for moderate and severe AD in urban China.

Purpose of the Study:

  • To describe clinical management pathways for moderate and severe Alzheimer's disease (AD) patients in urban China.
  • To quantify healthcare resource utilization and associated costs for AD management.

Main Methods:

  • A Delphi panel of 11 experts (9 physicians, 2 hospital administrators) from urban China was convened.
  • Two rounds of interviews were conducted, followed by a consensus meeting to determine resource utilization rates, unit costs, and caregiving time.

Main Results:

  • Moderate to severe Alzheimer's disease (AD) is commonly diagnosed, with loss of independence and aggression driving healthcare resource use.
  • Dependent/aggressive AD patients have high hospitalization rates (70-90%), while dependent/non-aggressive patients are more often placed in nursing homes (80%).
  • Caregiver time ranges from 1-3 hours/day for independent patients to 12-15 hours/day for dependent patients. Age-related comorbidities complicate management and increase hospitalization costs.

Conclusions:

  • The Delphi panel method efficiently gathered data on healthcare resource use and costs for moderate to severe Alzheimer's disease (AD) in urban China.
  • Study findings offer valuable insights for decision-makers to enhance healthcare policies, resource planning, and economic evaluations of AD therapies.
Abstract

Related Concept Videos

Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Dementia01:30

Dementia

Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
709
Drug Dosing: Geriatric Patients01:15

Drug Dosing: Geriatric Patients

Elderly individuals encompass a diverse population with varying degrees of age-related physiological changes. Defining the elderly presents challenges, as the geriatric population is often arbitrarily categorized as individuals older than 65. However, many individuals in this group lead active and healthy lives, with an increasing number surpassing 85 years and falling into the older elderly category. Physiological changes associated with aging impact performance capacity and homeostatic...
357